Shelter Pharma Ltd.
BBSE:SHELTER47.00
INR
0.00
(0.00%)
ISIN
INE013V01011
Return %
Stock
S&P 500
1Y
7.43
14.20
3Y
15.79
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Mustakkumar Luhar
- Full Time Employees
- 69
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 501, Sakar 4 Ahmedabad GJ India 380006
- IPO Date
- Aug 23, 2023
- Website
- shelter.co.in
- Similar Companies
- Business
- Shelter Pharma Ltd. manufactures and markets herbal Ayurvedic medicines and formulations for human healthcare, veterinary care, and poultry health in India. The company offers an extensive portfolio of over-the-counter and ethical pharmaceutical products, including for human use Adalpin-SP Tablet, Alkaliser Syrup, B-Kleen Liquid and Tablets for blood purification and skin health, Baldeepak Syrup, Banatone Syrup, Beta Gulcan, Bipinyl Capsule, Chymocure, Cocoment Ointment, Cough Nal Syrup, Dia Dys Tablet, D3 Cure, Diabetone Tablet for diabetes management, Emune 19 Syrup and Capsule for immunity boosting, Freshol Hand Cleanser, Happy Forte Capsule for vitality, Gynoshel Liquid, Gasoshel Tablet for gas and acidity relief, Lemon Barley Water for kidney health and detoxification, Livodin 12 Syrup for liver support, Sherolax Laxative Tablet, Stonyl Tablet for kidney stones, and Wormishel Tablet; for veterinary and poultry use Anical Oral, Bijrol Liquid, Biotone Plus Liquid, Bovi Cal-P, Buta-B Bolus, Cal Boost Vet, Calci D Plus, Gasoshel Tablet, Stonyl Tablet, and Sherolax Tablets, among others. Shelter Pharma Ltd., founded in 1965 and headquartered in Ahmedabad, Gujarat, operates GMP, HACCP, and ISO 9001:2015 certified facilities focused on in-house R&D and Ayurvedic expertise, serving domestic markets through pharma distributors, retailers, and veterinarians. In recent developments, the company converted multiple tranches of convertible warrants into equity shares, including 7.35 lakh warrants at Rs 42.25 per share in November 2025 raising Rs 2.33 crore from promoters Shakil Nisarahmed Sabugar and Mustaqim Nisarahmed Sabugar, 11.28 lakh warrants in October 2025 raising Rs 3.57 crore, and 13.14 lakh warrants earlier in October 2025 raising Rs 4.16 crore, increasing paid-up capital to Rs 16.33 crore; it also secured a purchase order from Taha Drugs & Chemicals Co. for Joemega Capsule and Vitamins Tablets in November 2025 and received funding approvals for up to Rs 385 million through warrants in mid-2025.